167 related articles for article (PubMed ID: 27046219)
21. A case of bupropion-induced stuttering.
Fetterolf F; Marceau M
Gen Hosp Psychiatry; 2013; 35(5):574.e7-8. PubMed ID: 22959418
[TBL] [Abstract][Full Text] [Related]
22. A Case of Fluoxetine-Induced Lower Extremity Ecchymosis.
Çetin B; Ergelen M
Prim Care Companion CNS Disord; 2017 Jun; 19(3):. PubMed ID: 28636812
[No Abstract] [Full Text] [Related]
23. Effect of bupropion on sexual dysfunction induced by fluoxetine: a case report of hypersexuality.
Chollet CA; Andreatini R
J Clin Psychiatry; 2003 Oct; 64(10):1268-9. PubMed ID: 14658981
[No Abstract] [Full Text] [Related]
24. Dose-Dependent Inhibition of CYP2D6 by Bupropion in Patients With Depression.
Hole K; Arnestad M; Molden E; Haslemo T
J Clin Psychopharmacol; 2021 May-Jun 01; 41(3):281-285. PubMed ID: 33905640
[TBL] [Abstract][Full Text] [Related]
25. Restless legs syndrome associated with the combined use of duloxetine plus paroxetine.
Nikolaou KN; Michopoulos I; Douzenis A; Papazahos C; Papageorgiou C; Gournellis R
J Clin Psychopharmacol; 2015 Jun; 35(3):345-6. PubMed ID: 25815756
[No Abstract] [Full Text] [Related]
26. Eight-week, placebo-controlled, double-blind comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR.
Hewett K; Chrzanowski W; Schmitz M; Savela A; Milanova V; Gee M; Krishen A; Millen L; Leary MO; Modell J
J Psychopharmacol; 2009 Jul; 23(5):531-8. PubMed ID: 18635695
[TBL] [Abstract][Full Text] [Related]
27. Serum concentrations of hydroxybupropion for dose optimization of depressed patients treated with bupropion.
Laib AK; Brünen S; Pfeifer P; Vincent P; Hiemke C
Ther Drug Monit; 2014 Aug; 36(4):473-9. PubMed ID: 24452068
[TBL] [Abstract][Full Text] [Related]
28. Common Polymorphisms of CYP2B6 Influence Stereoselective Bupropion Disposition.
Kharasch ED; Crafford A
Clin Pharmacol Ther; 2019 Jan; 105(1):142-152. PubMed ID: 29756345
[TBL] [Abstract][Full Text] [Related]
29. Bupropion Hydrochloride.
Khan SR; Berendt RT; Ellison CD; Ciavarella AB; Asafu-Adjaye E; Khan MA; Faustino PJ
Profiles Drug Subst Excip Relat Methodol; 2016; 41():1-30. PubMed ID: 26940167
[TBL] [Abstract][Full Text] [Related]
30. Cognitive predictors of treatment response to bupropion and cognitive effects of bupropion in patients with major depressive disorder.
Herrera-Guzmán I; Gudayol-Ferré E; Lira-Mandujano J; Herrera-Abarca J; Herrera-Guzmán D; Montoya-Pérez K; Guardia-Olmos J
Psychiatry Res; 2008 Jul; 160(1):72-82. PubMed ID: 18501971
[TBL] [Abstract][Full Text] [Related]
31. Subtherapeutic bupropion and hydroxybupropion serum concentrations in a patient with CYP2C19*1/*17 genotype suggesting a rapid metabolizer status.
Gaebler AJ; Schneider KL; Stingl JC; Paulzen M
Pharmacogenomics J; 2020 Dec; 20(6):840-844. PubMed ID: 32475982
[TBL] [Abstract][Full Text] [Related]
32. Effectiveness of a quantitative electroencephalographic biomarker for predicting differential response or remission with escitalopram and bupropion in major depressive disorder.
Leuchter AF; Cook IA; Gilmer WS; Marangell LB; Burgoyne KS; Howland RH; Trivedi MH; Zisook S; Jain R; Fava M; Iosifescu D; Greenwald S
Psychiatry Res; 2009 Sep; 169(2):132-8. PubMed ID: 19709754
[TBL] [Abstract][Full Text] [Related]
33. Combining Antidepressants with β-Blockers: Evidence of a Clinically Significant CYP2D6 Drug Interaction.
Shin J; Hills NK; Finley PR
Pharmacotherapy; 2020 Jun; 40(6):507-516. PubMed ID: 32342526
[TBL] [Abstract][Full Text] [Related]
34. Bupropion sustained release: a therapeutic overview.
Davidson JR; Connor KM
J Clin Psychiatry; 1998; 59 Suppl 4():25-31. PubMed ID: 9554318
[TBL] [Abstract][Full Text] [Related]
35. Fatigue as a core symptom in major depressive disorder: overview and the role of bupropion.
Pae CU; Lim HK; Han C; Patkar AA; Steffens DC; Masand PS; Lee C
Expert Rev Neurother; 2007 Oct; 7(10):1251-63. PubMed ID: 17939764
[TBL] [Abstract][Full Text] [Related]
36. Bupropion.
Nurs Times; 2006 Jan 3-9; 102(1):31. PubMed ID: 16425753
[No Abstract] [Full Text] [Related]
37. Combined bupropion-levodopa-trazodone therapy of sleep-related eating and sleep disruption in two adults with chemical dependency.
Schenck CH; Mahowald MW
Sleep; 2000 Aug; 23(5):587-8. PubMed ID: 10947025
[No Abstract] [Full Text] [Related]
38. Steady-state clinical pharmacokinetics of bupropion extended-release in youths.
Daviss WB; Perel JM; Birmaher B; Rudolph GR; Melhem I; Axelson DA; Brent DA
J Am Acad Child Adolesc Psychiatry; 2006 Dec; 45(12):1503-9. PubMed ID: 17135996
[TBL] [Abstract][Full Text] [Related]
39. Enhancement of nootropic effect of duloxetine and bupropion by caffeine in mice.
Kale PP; Addepalli V
Indian J Pharmacol; 2015; 47(2):199-201. PubMed ID: 25878382
[TBL] [Abstract][Full Text] [Related]
40. Toward personalized therapy for smoking cessation: a randomized placebo-controlled trial of bupropion.
Patterson F; Schnoll RA; Wileyto EP; Pinto A; Epstein LH; Shields PG; Hawk LW; Tyndale RF; Benowitz N; Lerman C
Clin Pharmacol Ther; 2008 Sep; 84(3):320-5. PubMed ID: 18388868
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
